Terug

Nanosonics Limited

Datakwaliteit: 100%

NNCSF

OTC Healthcare Medical - Instruments & Supplies

€ 2,19

▼ € 0,11 (-4,78%)

Marktkapitalisatie: 664,36M

Dagbereik

€ 2,19 € 2,19

52-Weeksbereik

€ 2,14 € 3,30

Volume

100

50D / 200D Gem.

€ 2,70 / € 2,73

Vorige Slotkoers

€ 2,19

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek	Aandeel	Sector Mediaan
P/E	32,1	0,2
P/B	3,2	3,0
ROE %	10,6	3,5
Net Margin %	10,4	3,8
Rev Growth 5Y %	18,2	9,7
D/E	0,0	0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode	WPA Sch.	Omzet Sch.	Analisten
FY2030	€ 0,00 € 0,00 – € 0,00	379,10M	0
FY2029	€ 0,13 € 0,13 – € 0,14	295,47M	1
FY2028	€ 0,09 € 0,09 – € 0,10	275,45M	1

Earnings Surprises

Last 8 quarters

Quarter	Est. EPS	Actual EPS	Surprise
2026-02-24	€ 0,04	€ 0,02	-46,2%
2025-08-24	€ 0,02	€ 0,02	+16,8%
2025-02-19	€ 0,01	€ 0,02	+46,7%
2024-08-26	€ 0,01	€ 0,01	+27,2%
2024-02-26	€ 0,01	€ 0,01	+51,3%
2023-06-30	€ 0,01	€ 0,02	+54,3%
2022-12-31	€ 0,02	€ 0,02	+12,6%
2022-06-30	-€ 0,01	€ 0,00	+97,8%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 18,22% annually over 5 years — strong growth

Earnings grew 59,39% over the past year

ROE of 10,55% — decent returns on equity

Debt/Equity of 0,04 — conservative balance sheet

Generating 35,26M in free cash flow

P/E of 32,13 — premium valuation

Groei

Revenue Growth (5Y)

18,22%

Revenue (1Y)17,01%

Earnings (1Y)59,39%

FCF Growth (3Y)33,64%

Kwaliteit

Return on Equity

10,55%

ROIC3,08%

Net Margin10,39%

Op. Margin4,49%

Veiligheid

Debt / Equity

0,04

Current Ratio5,66

Interest Coverage6,10

Waardering

P/E Ratio

32,13

Forward P/E42,69

P/B Ratio3,16

EV/EBITDA57,22

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	17,01%	Revenue Growth (3Y)	8,97%
Earnings Growth (1Y)	59,39%	Earnings Growth (3Y)	1,97%
Revenue Growth (5Y)	18,22%	Earnings Growth (5Y)	24,60%
Profitability
Revenue (TTM)	198,93M	Net Income (TTM)	20,68M
ROE	10,55%	ROA	7,59%
Gross Margin	78,25%	Operating Margin	4,49%
Net Margin	10,39%	Free Cash Flow (TTM)	35,26M
ROIC	3,08%	FCF Growth (3Y)	33,64%
Safety
Debt / Equity	0,04	Current Ratio	5,66
Interest Coverage	6,10
Dividends
Dividend Yield	0,00%	Payout Ratio	0,00%
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	32,13	Forward P/E	42,69
P/B Ratio	3,16	P/S Ratio	3,34
PEG Ratio	0,84	Forward PEG	N/A
EV/EBITDA	57,22	Fwd EV/EBITDA	18,40
Forward P/S	2,92	Fwd Earnings Yield	2,34%
FCF Yield	5,31%
Market Cap	664,36M	Enterprise Value	510,75M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	198,93M	170,01M	167,52M	119,73M	101,83M
Net Income	20,68M	12,97M	19,88M	3,74M	8,58M
EPS (Diluted)	0,07	0,04	0,06	0,01	0,03
Gross Profit	155,66M	132,44M	125,66M	86,15M	74,91M
Operating Income	8,93M	9,12M	18,00M	792.000,0	8,38M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	272,48M	237,34M	226,08M	193,24M	164,58M
Total Liabilities	62,57M	55,14M	62,22M	54,55M	29,01M
Shareholders' Equity	209,91M	182,20M	163,86M	138,69M	135,57M
Total Debt	7,69M	9,30M	10,72M	11,71M	2,49M
Cash & Equivalents	161,29M	129,55M	112,16M	94,51M	96,03M
Current Assets	225,32M	198,45M	181,24M	150,50M	142,15M
Current Liabilities	39,79M	32,23M	33,03M	28,64M	19,54M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)

Rank = position among all matches

Custom Cash Flow Compounder

#855 of 1049

Recente Activiteit

Ingestapt Cash Flow Compounder

Mar 24, 2026